期刊
ADVANCED SCIENCE
卷 7, 期 12, 页码 -出版社
WILEY
DOI: 10.1002/advs.201902227
关键词
antibiotic adjuvant; metformin; multidrug resistant bacteria; tetracycline
资金
- National Key Research and Development Program of China [2018YFA0903400]
- National Natural Science Foundation of China [31872526]
- Natural Science Foundation of Jiangsu Province of China [BK20190893]
- China Postdoctoral Science Foundation [2019M651984]
- Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)
- Lift Engineering of Young Talents of Jiangsu Association for Science and Technology
Highly persistent incidence of multidrug resistant (MDR) bacterial pathogens constitutes a global burden for public health. An alternative strategy to alleviate such a crisis is to identify promising compounds to restore antibiotics activity against MDR bacteria. It is reported that the antidiabetic drug metformin exhibits the potentiation effect on tetracycline antibiotics, particularly doxycycline and minocycline, against MDR S. aureus, E. faecalis, E. coli, and S. enteritidis. Mechanistic studies demonstrate that metformin promotes intracellular accumulation of doxycycline in tetracycline-resistant E. coli. In addition, metformin boosts the immune response and alleviates the inflammatory responses in vitro. Last, metformin fully restores the activity of doxycycline in three animal infection models. Collectively, these results reveal the potential of metformin as a novel tetracyclines adjuvant to circumvent MDR bacterial pathogens and to improve the treatment outcome of recalcitrant infections.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据